IT has been customary to treat carcinoma of the breast post-operatively, with a tumour dose of 2,000-4,000 r in two to four weeks and this is still widely practised. Since October 1949, the techniques advocated by Baclesse and Lenz using a higher dosage over a longer overall time have been used in Portsmouth.
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Portsmouth IT has been customary to treat carcinoma of the breast post-operatively, with a tumour dose of 2,000-4,000 r in two to four weeks and this is still widely practised. Since October 1949, the techniques advocated by Baclesse and Lenz using a higher dosage over a longer overall time have been used in Portsmouth. The first groups of cases were treated prior to this time under the aegis of A. G. C. Taylor of Southampton to whom I am indebted for permission to include them.
An analysis of the very varied dose-time factors used by Baclesse in treating laryngeal carcinoma did not reveal any clear optimum. The mean dose of 5,500 r given in a mean time of eight weeks, modified a little with growing experience, has been used in the second group. The internal mammary chain was also included in this group, whereas in the short course series only the chest wall, axilla and supraclavicular areas were covered.
It is only fair to say that 28 patients who had a genuine simple mastectomy subsequent to October 1949 were included in the short course though only one of these fell into Stage IV. Any bias therefore is in favour of the shorter treatments. Otherwise all patients seen subsequent to October 1949 are included in the ten-week course whether they had radical treatment or not. By general agreement with the surgeons Stage I patients without glandular involvement histologically were not given irradiation and are excluded from the figures presented. Those having recurrent carcinoma when first seen are excluded from both series. Stage I patients are therefore made up of those with glandular involvement on histological examination, and a few patients with growths in the inner quadrants or close to the edge of the breast, where the surgeons concerned felt their prognosis might be helped by irradiation. STAGING Manchester Staging has been used throughout. As Stage I were treated by operation only, these had to be a little more strictly defined, otherwise a 70-85% five-year survival could not be expected. Tumours tethered to pectoralis major were relegated to Stage III as were those which were large in relation to the size of the breast. Haagensen and Stout (1951) have shown that the prognosis in larger tumours is a good deal worse, and put the upper limit for Stage I at 6 cm., while Ducuing, Tailhefer, and Baclesse (1948) put it as low as 3 cm. McWhirter, with less strict criteria, has a 60% five-year survival in the Stage quoted for him.
The distribution by stage in each group is a little different, there being only 16% of Stage I cases in the long course as opposed to 27 % in the short. Patients not receiving radical therapy constituted 27 % of the short course but only 16% of the long. The main reason for this lies in those judged too ill or too old. Failure to complete treatment and the presence of distant metastases affect each group identically.
As the surgeons became more familiar with the relatively mild reactions, pre-operative irradiation was tried in some late cases. A photograph of a patient in Stage III who had a radical mastectomy six weeks after her radiotherapy and a Thiersch graft with a 100% take, was shown. This illustrated the healthy state of the tumour bed and that natural repair and resistance were unimpaired. 6 out of 15 such patients are alive and free of disease at the end of five years, which though encouraging, is of no statistical value. HISTOLOGY This is available for all living patients. 8 survivals in one group and 6 in the other have been excluded, as histology was not available. Analysis of the type of surgery performed in combination with irradiation showed that 79 % in the short course and 71 % in the long course had some form of surgery and half those operated on in the short course had a simple mastectomy only, while just under a quarter in the long course had a simple mastectomy with removal of involved lymph nodes. Radical mastectomies were performed on the remainder. 21 % in the short course and 29% in the long had no surgery. Table I shows the overall survival in each group and at each stage. The improvement in results in the long course is suggestive but not statistically significant. It would appear more beneficial to the more advanced cases where surgery alone achieves so much less.
From the patient's point of view the best result is not just survival, but to undergo the initial treatment and to remain free of symptoms and signs, therefore not requiring any further therapy. Those in the column labelled "recurrence free" satisfy these criteria. No patient received prophylactic ovarian ablation. McWhirter is quoted (Smithers et al., 1952) as having 42-9 % alive and only 31-7 % recurrence free.
The three-year recurrence-free rates were compared with five-year survivals and found to give 4-8 % too optimistic an estimate, though this shorter term criterion might be useful in comparative studies. Table II shows the recurrence rates in the treated area: skin, axillary, supraclavicular and parasternal sites are all included. Haagensen with very strict criteria of operability gives 12-5 % in the axilla and chest wall only. White (1946) at the Roosevelt Hospital gives 22-6%.
Baclesse and Tailhefer (Ducuing et al., 1948) quote 2% for a very strictly defined Stage I, 6% for Stage II and 30% for Stage III with surgery alone. Irradiation only succeeded in improving the Stage III rate to 12%, though their Stage III unlike the Manchester one included those with involved nodes above the clavicle.
Finally I should like to offer some evidence that treatment is worth while and that the repetition of the 39-month average survival deserves less publicity than it has received.
Statistics must be used with discretion and freak occurrences must not bias them unduly. Likewise the length of history is too unreliable to be included. None of the untreated tumours was confirmed histologically when first seen. Daland (1927) on 100 consecutive cases 1-4-1 65 years may be quoted for comparison. The median survival for all cases is two and a half and three years respectively.
To summarize:
The ten-week course gives a more flexible method of treatment and may be used either before or after operation.
It produces a significantly lower local recurrence rate. The five-year survival rates especially the recurrence-free rates are equal to the best published, when the omission of the bulk of Stage I cases is taken into account.
The local recurrence rate, the most precise measure of the effectiveness of radiotherapy, is markedly diminished by extending treatment to a high dose over ten weeks.
Treatment undoubtedly affects the course of the disease.
No patient in the untreated series was symptom-and sign-free, nearly one-third of those treated had this additional comfort and some hope at least was given to all.
Acknowledgement London THE clinical progress of patients with carcinoma of the breast is so variable that perhaps we should be nearer to solving the problems of treatment if we regarded this disease as being caused, not by a single tumour type, but by a group of tumours with a broad spectrum of malignancy.
The outcome of treatment may be quite different even in patients of similar age, with the same duration of symptoms and with tumours of comparable clinical extent. In addition, identical lines of treatment may give variable results, and equally good results have been obtained by radical and more conservative procedures. It is facts such as these which make the management of operable breast cancer still a subject for debate, even though ninety years have elapsed since the first type of radical mastectomy was introduced by Moore of the Middlesex Hospital (Moore, 1867). The chief purpose of this paper is to present evidence in support of the view that differing opinions regarding treatment have arisen largely from comparing results in groups of patients not strictly comparable, and to propose a more accurate classification of the disease.
The generally accepted classification of carcinoma of the breast provides a guide only to the obvious extent of the tumour. Early death in what appear to have been favourable cases must indicate the presence of highly malignant occult metastases at the time of treatment. Delayed death in advanced cases points to metastases of low-grade malignancy. The failure to detect subclinical metastases in so-called early cases and the inability to assess the speed with which such metastases are likely to develop, are responsible for many of the discrepancies which result from staging.
Can staging be made more accurate? The fallacy of trying to decide whether the axillary lymph nodes are involved or not by clinical examination is well known. About 40% of non-palpable nodes show histological invasion, and some 20% of palpable nodes are histologically free (Harnett, 1948; Haagensen, 1956) . The routine microscopic examination of lymph glands from the axilla and also the internal mammary chain (Handley and Thackray, 1954) will, no doubt, add to the value of staging, but even this procedure is open to considerable error. Thus, Saphir and Amromin (1948) find that serial sections demonstrate axillary involvement in one-third of cases previously reported as being histologically free.
Staging, in its present form, will always be of limited value in the study of breast cancer, and it is difficult to see how further improvements in this type of classification can be brought about. Hence, a method of determining the potential malignancy of the tumour may provide a more accurate guide to prognosis than measuring the clinical extent of the growth. By "potential malignancy" is meant the proneness of the tumour to metastasize early or late.
Some indication of the degree of malignancy of breast cancer can be obtained from the histological architecture of the tumour, and it is convenient to express this in terms of a simple numerical grading system. This provides a guide to the likelihood of involvement of those structures not adequately considered by staging, and also to the speed with which metastases may develop, give rise to symptoms and finally cause death (Bloom and Richardson, 1957) . Grading of carcinoma of the breast was introduced into this country by Patey and Scarff (1928) who followed the principles formulated by Greenough (1925) in the United States. The method, which is simple to apply and has proved an effective guide to prognosis, is based on three histological criteria, namely, degree of tubule formation, regularity of nuclei, and frequency of hyperchromatic and mitotic figures (Bloom, 1950a) . Taking the histological picture as a whole each tumour is then classified as being of low, intermediate or high malignancy, grades I, II and III respectively (Figs. 1-3 ). Needless to say, these three types of tumour are not entities, but merely represent arbitrary subdivisions of a continuous malignant scale. Details and problems of this technique of grading have been described fully elsewhere (Bloom and Richardson, 1957) .
